Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As Improvements In Anxiety Symptoms Were Also Observed In Patients Taking CAPLYTA As Measured By The Generalized Anxiety Disorder Questionnaire
Intra-Cellular Therapies在美國神經心理藥理學年會上展示了CAPLYTA輔助治療重度抑鬱症第三階段項目的數據；數據顯示，服用CAPLYTA的患者在緩解和反應的有效率上表現良好，同時在服用CAPLYTA的患者中也觀察到了焦慮症狀的改善，改進通過廣泛性焦慮障礙問卷測量。
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
這些展示補充了來自兩項關鍵研究（501和502研究）的新數據，這些研究評估了lumateperone作爲重度抑鬱症治療的輔助療法。
Data shows robust remission and response efficacy rates in patients taking CAPLYTA
數據顯示，服用CAPLYTA的患者在緩解和反應的有效率上表現良好。
Robust improvements in anxiety symptoms were also observed in patients taking CAPLYTA as measured by the Generalized Anxiety Disorder Questionnaire (GAD-7)
在服用CAPLYTA的患者中，焦慮症狀也得到了顯著改善，這一結果通過廣泛性焦慮障礙問卷（GAD-7）進行測量。
Pooled safety and tolerability data from Studies 501 and 502 show favorable safety and tolerability profile for CAPLYTA consistent with prior studies
來自501和502研究的合併安全性和耐受性數據顯示，CAPLYTA的安全性和耐受性特徵與之前的研究一致，表現良好。
A post-hoc analysis from Study 403 in mixed features shows CAPLYTA significantly improved anhedonia symptoms as measured by the MADRS anhedonia factor score
來自403研究的後期分析顯示，CAPLYTA顯著改善了以MADRS快感缺失因子評分測量的快感缺失症狀。
BEDMINSTER, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced presentations at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) which included new efficacy, safety, and tolerability analyses from its CAPLYTA adjunctive major depressive disorder (MDD) pivotal program.
新澤西州貝德敏斯特，2024年12月11日（全球新聞社）-- Intra-Cellular Therapies, Inc.（納斯達克：ITCI），是一家專注於中央神經系統（CNS）疾病治療藥物開發和商業化的生物製藥公司，今天在第63屆美國神經心理藥理學年會上宣佈了展示，包括其CAPLYTA輔助重度抑鬱症（MDD）關鍵項目的新有效性、安全性和耐受性分析。
